A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease
A 54-year-old, non-smoking woman was diagnosed as stage ⅣB adenocarcinoma with widespread bone metastasis (cT4N2M1c) in the First Affiliated Hospital, Zhejiang University School of Medicine. Immunohistochemistry result showed the presence of anaplastic lymphoma kinase (ALK) gene rearrangement; next-generation sequencing (NGS) indicated EML4-ALK fusion (E6:A20) with concurrent CCDC148-ALK (C1:A20), PKDCC-ALK (Pintergenic:A20)and VIT-ALK (V15:A20) fusions. After 32 weeks of alectinib treatment, the patient complained cough and exertional chest distress but had no sign of infection. Computed tomography (CT) showed bilateral diffuse ground glass opacities, suggesting a diagnosis of alectinib-related interstitial lung disease (ILD). Following corticosteroid treatment and discontinuation of alectinib, clinical presentations and CT scan gradually improved, but the primary lung lesions enlarged during the regular follow-up. The administration of crizotinib was then initiated and the disease was stable for 25 months without recurrence of primary lung lesions and ILD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences - 52(2023), 5 vom: 08. Okt., Seite 583-587 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
阿来替尼治疗非小细胞肺癌患者发生间质性肺疾病再用克唑替尼治疗有效 |
|---|
| Beteiligte Personen: |
Sun, Wenjia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
53AH36668S |
|---|
| Anmerkungen: |
Date Completed 31.10.2023 Date Revised 10.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3724/zdxbyxb-2023-0319 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363914072 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363914072 | ||
| 003 | DE-627 | ||
| 005 | 20231226094340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3724/zdxbyxb-2023-0319 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1212.xml |
| 035 | |a (DE-627)NLM363914072 | ||
| 035 | |a (NLM)37899398 | ||
| 035 | |a (PII)1008-9292(2023)05-0583-05 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Wenjia |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease |
| 246 | 3 | 3 | |a 阿来替尼治疗非小细胞肺癌患者发生间质性肺疾病再用克唑替尼治疗有效 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.10.2023 | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A 54-year-old, non-smoking woman was diagnosed as stage ⅣB adenocarcinoma with widespread bone metastasis (cT4N2M1c) in the First Affiliated Hospital, Zhejiang University School of Medicine. Immunohistochemistry result showed the presence of anaplastic lymphoma kinase (ALK) gene rearrangement; next-generation sequencing (NGS) indicated EML4-ALK fusion (E6:A20) with concurrent CCDC148-ALK (C1:A20), PKDCC-ALK (Pintergenic:A20)and VIT-ALK (V15:A20) fusions. After 32 weeks of alectinib treatment, the patient complained cough and exertional chest distress but had no sign of infection. Computed tomography (CT) showed bilateral diffuse ground glass opacities, suggesting a diagnosis of alectinib-related interstitial lung disease (ILD). Following corticosteroid treatment and discontinuation of alectinib, clinical presentations and CT scan gradually improved, but the primary lung lesions enlarged during the regular follow-up. The administration of crizotinib was then initiated and the disease was stable for 25 months without recurrence of primary lung lesions and ILD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adenocarcinoma | |
| 650 | 4 | |a Case report | |
| 650 | 4 | |a Interstitial lung disease | |
| 650 | 4 | |a Targeted therapy | |
| 650 | 4 | |a Tyrosine kinase inhibitor | |
| 650 | 7 | |a Crizotinib |2 NLM | |
| 650 | 7 | |a 53AH36668S |2 NLM | |
| 650 | 7 | |a alectinib |2 NLM | |
| 650 | 7 | |a LIJ4CT1Z3Y |2 NLM | |
| 650 | 7 | |a Anaplastic Lymphoma Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Zheng, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jianya |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jianying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences |d 2002 |g 52(2023), 5 vom: 08. Okt., Seite 583-587 |w (DE-627)NLM123207037 |x 1008-9292 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2023 |g number:5 |g day:08 |g month:10 |g pages:583-587 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3724/zdxbyxb-2023-0319 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2023 |e 5 |b 08 |c 10 |h 583-587 | ||